IL4I1-driven AHR signature: a new avenue for cancer therapy

Signal Transduct Target Ther. 2021 Mar 10;6(1):118. doi: 10.1038/s41392-021-00529-z.

Zuli Wang^{1

2}, Tiansheng Li^{1

2}, Chao Mao^{1

2}, Wenliang Liu³, Yongguang Tao^{4

5

6}

¹ NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
² Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan, China.
³ Department of Thoracic Surgery, Hunan Key Laboratory of Early Diagnosis and Precision Therapy in Lung Cancer, Second Xiangya Hospital, Central South University, Changsha, Hunan, China. liuwenliang@csu.edu.cn.
⁴ NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China. taoyong@csu.edu.cn.
⁵ Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan, China. taoyong@csu.edu.cn.
⁶ Department of Thoracic Surgery, Hunan Key Laboratory of Early Diagnosis and Precision Therapy in Lung Cancer, Second Xiangya Hospital, Central South University, Changsha, Hunan, China. taoyong@csu.edu.cn.

No abstract available

Publication types